Madrid has excluded costly genetic tests from the lab now managed by Quirónsalud. The move changes how rare disease and cancer risk diagnostics are handled for 1.4 million residents. Staff contracts and service delivery face major shifts.
The Community of Madrid has removed all genetic diagnostic tests from the laboratory in San Sebastián de los Reyes, just as management of the facility passes from Ribera Salud to Quirónsalud. This decision, outlined in the contract terms, means the most expensive analyses—used for rare diseases and cancer risk—will no longer be processed at the center, which serves six regional hospitals and 1.4 million people. The change is expected to bring significant savings for Quirónsalud, which secured the five-year contract by offering €120 million in compensation, underbidding its long-time rival Ribera Salud.
Genetic tests, which can cost between €500 and €3,000 per case, have been a major expense for the lab since its opening in 2010. By excluding these tests, Quirónsalud aims to streamline costs, especially as the company also seeks to start with a workforce that has no accrued seniority rights. This approach has sparked conflict with the existing staff of 249, whose contracts Quirónsalud has declined to inherit, despite union demands. Employees now face a choice: accept new contracts with less favorable terms or risk unemployment, as Ribera Salud refuses to issue formal dismissals that would allow them to claim benefits.
The Community of Madrid will now directly manage genetic diagnostics, assigning them to five major public hospitals. Officials argue that direct oversight is more efficient, given the rapid evolution of genetic medicine and the growing demands from Spain's Ministry of Health. This marks a notable shift for a region that has long championed outsourcing in healthcare. The regional health department has assured unions that the six affected genetic lab workers—four technicians and two geneticists—will have their private sector experience recognized in public hiring processes, potentially easing their transition into the public system.
Quirónsalud, for its part, claims that around 60% of the previous staff have already joined its team, insisting that no acquired rights are lost by switching employers. However, union sources report that new contracts often include less favorable conditions, such as expanded workdays and the possibility of reassignment to any Quirónsalud facility in Madrid. The dispute between Quirónsalud and Ribera Salud has escalated, with legal warnings exchanged and both companies blaming each other for the tense handover. The financial terms also reflect the new landscape: while Ribera Salud received €19 million annually, Quirónsalud will be paid €24 million per year, with promises to invest in new laboratory equipment.
Madrid's move to bring genetic testing back under public control comes as other Spanish regions also review how social and health services are delivered. For example, Catalonia recently allocated €30 million to identify families missing out on social aid, aiming to improve access for vulnerable groups—a development detailed in this report on targeted welfare expansion. These shifts highlight ongoing debates over efficiency, cost, and the role of private providers in Spain's public services. Genetic diagnostics remain available to Madrid residents, but the pathway and provider have changed, with practical consequences for patients, staff, and the regional health budget.
Genetic testing is increasingly central to modern healthcare, especially for early detection of hereditary conditions and cancer predisposition. The decision to centralize these services in public hospitals may allow for more flexible adaptation to new technologies and clinical guidelines. However, the transition period has exposed vulnerabilities in labor protections and continuity of care, issues that continue to shape Spain's evolving healthcare landscape.
